Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
AssigneeWyeth
InventorsJudy Crabtree, Heather Harris, Scott Jelinsky, Xiaochun Zhang, Bryan Peano
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for the identification of effector molecules useful in the treatment of vulvovaginal atrophy. Methods of treating vulvovaginal atrophy comprising administering the effector molecules are also disclosed.
Claims61
A method of treating vulvovaginal atrophy comprising administering to a mammal in need thereof a therapeutically effective amount of an effector molecule which modulates the activity of HIF1α or betacellulin receptors.
A method of screening for effector molecules which ameliorate vulvovaginal atrophy comprising:
- (a) administering estrogen to a test subject;
- (b) isolating mRNA from the vaginal cells of the test subject;
- (c) comparing mRNA expression levels between the mRNA isolated in step (b) with mRNA isolated from a control subject;
- (d) identifying a target mRNA based on the comparison of step (c);
- and
- (e) identifying an effector molecule which modulates the activity of the target mRNA of step (d).
An effector molecule identified by any of claims 3647.
A method of treating vulvovaginal atrophy comprising:
- (a) administering estrogen to a test subject;
- (b) isolating mRNA from the vaginal cells of the test subject;
- (c) comparing mRNA expression levels between the mRNA isolated in step (b) with mRNA isolated from a control subject;
- (d) identifying a target mRNA based on the comparison of step (c);
- (e) identifying an effector molecule which modulates the activity of the target mRNA of step (d);
- and
- (f) administering a therapeutically effective amount of the effector molecule of step (e) to a mammal in need of vulvovaginal atrophy treatment.
A method of identifying target mRNA which is regulated by estrogen comprising:
- (a) administering estrogen to a test subject;
- (b) isolating mRNA from the vaginal cells of the test subject;
- (c) comparing mRNA expression levels between the mRNA isolated in step (b) with mRNA isolated from a control subject;
- and
- (d) identifying a target mRNA based on the comparison of step (c).
Dependencies are inferred from the claim text.